Latest Island Pharmaceuticals (ASX:ILA) News

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

Small caps drove the week, with battery, resources and education names posting the biggest gains. Deal news, funding rounds and fresh drilling plans kept traders busy, while a few discounted raisings hit hard.

Healthcare stocks split into two camps this week: names with fresh data or contracts found buyers, while capital raisings and trial shock sent others sharply lower. The biggest move came from Cynata’s return to trade, but steady progress in Alzheimer’s, oncology, diagnostics and aged care software also kept the sector busy.

Island Pharmaceuticals has won a key regulatory boost as the US FDA granted Orphan Drug Designation to Galidesivir for post-exposure prophylaxis of Marburg virus disease, enhancing its commercial and development prospects.

Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.

Healthcare shares were driven by regulation, capital and commercial deals this week. The biggest moves came from companies that either moved closer to US sales or raised cash to get there.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has expanded its partnership with USAMRIID to conduct a pivotal Galidesivir dose optimisation study against Marburg virus, targeting topline results in the second half of 2026.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Island Pharmaceuticals has appointed Raymond Taylor, a former BioCryst executive with deep Galidesivir expertise and US government funding experience, to accelerate development and procurement efforts for its broad-spectrum antiviral amid rising viral threats.